

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/130318 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/IB2021/061926

(22) International Filing Date:
17 December 2021 (17.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/127,849 18 December 2020 (18.12.2020) US
63/213,973 23 June 2021 (23.06.2021) US

(71) Applicant: **MOMENTA PHARMACEUTICALS, INC.**
[US/US]; 301 Binney Street, Cambridge, MA 02142 (US).

(72) Inventors: **KURTAGIC, Elma**; 301 Binney Street, Cambridge, Massachusetts 02142 (US). **MEADOR, III, James W.**; 301 Binney Street, Cambridge, Massachusetts 02142 (US). **BENE DUCE, Christopher**; 301 Binney Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **FRANK, Eve L.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1

(57) Abstract: The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 ($\alpha 11\beta 1$), as well as methods of making and using such antibodies.



WO 2022/130318 A2